KR970061256A - 에스트로겐 작용제에 의해 질환을 치료하기 위한 조성물 - Google Patents
에스트로겐 작용제에 의해 질환을 치료하기 위한 조성물 Download PDFInfo
- Publication number
- KR970061256A KR970061256A KR1019970006291A KR19970006291A KR970061256A KR 970061256 A KR970061256 A KR 970061256A KR 1019970006291 A KR1019970006291 A KR 1019970006291A KR 19970006291 A KR19970006291 A KR 19970006291A KR 970061256 A KR970061256 A KR 970061256A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- composition
- pathological condition
- optionally substituted
- independently selected
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 13
- 239000000556 agonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 3
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract 3
- 102000003896 Myeloperoxidases Human genes 0.000 claims abstract 3
- 108090000235 Myeloperoxidases Proteins 0.000 claims abstract 3
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract 3
- 108090000190 Thrombin Proteins 0.000 claims abstract 3
- 102000012607 Thrombomodulin Human genes 0.000 claims abstract 3
- 108010079274 Thrombomodulin Proteins 0.000 claims abstract 3
- 206010067269 Uterine fibrosis Diseases 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 3
- 230000000302 ischemic effect Effects 0.000 claims abstract 3
- 210000004165 myocardium Anatomy 0.000 claims abstract 3
- 229960003604 testosterone Drugs 0.000 claims abstract 3
- 229960004072 thrombin Drugs 0.000 claims abstract 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract 2
- 230000007812 deficiency Effects 0.000 claims abstract 2
- 230000001575 pathological effect Effects 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- JMJKWWPXPGFVBE-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydro-1h-isoquinolin-6-ol Chemical compound C1CC2=CC(O)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)N1C1=CC=C(F)C=C1 JMJKWWPXPGFVBE-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- -1 bicyclic amine Chemical class 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
하기 화학식 (1)의 화합물은 알쯔하이머 질환, 생리전 증후군, 폐경기 부근 증후군, 트롬보모듈린 결핍, 자궁 섬유증, 과도한 미엘로퍼옥시다아제의 활성, 초과량의 트롬빈, 자기면역 질환, 허혈성 심근의 재관류 손상 및 테스토스테론 부전증을 치료하거나 예방하기 위해 유용하다 :
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 하기 화학식 (1)의 화합물 및 이의 광학적 및 기하학적 이성체의 유효량; 및 이의 무독성의 약리학적으로 허용되는 산부가염, N-옥시드, 에스테르 및 4급 알모늄염을 약학적으로 허용되는 담체, 희석제 또는 부형제와 함께 포함하는, 알쯔하이머 질환, 생리전 증후군, 폐경기 부근 증후군, 트롬보모듈린 결핍, 자궁 섬유증, 과도한 미엘로퍼옥시다아제의 활성, 과도한 트롬빈, 자기면역 질환, 허혈성 심근의 재관류 손상 및 테스토스테론 부전증으로 구성된 그룹에서 선택되는 병리학적 증상을 억제하기 위한 조성물 :상기 식에서, A는 CH2및 NR에서 선택되고; B, D 및 E는 CH 및 N으로부터 독립적으로 선택되고; Y는 (a) R4로부터 독립적으로 선택되는 1 내지 3개의 치환체에 의해 임의로 치환된 페닐; (b) R4로부터 독립적으로 선택되는 1 내지 3개의 치환체에 의해 임의로 치환된 나프틸; (c) R4로부터 독립적으로 선택되는 1 내지 2개의치환체에 의해 임의로 치환된 C3-C8사이클로알킬; (d) R4로부터 독립적으로 선택되는 1 내지 2개의 치환체에 의해 임의로 치환된 C3-C8사이클로알케닐; (e) R4로부터 독립적으로 선택되는 1 내지 3개의 치환체에 의해 임의로 치환된, -O-, -NR2- 및 -S(O)n-으로 구성된 그룹에서 선택되는 두개 이하의 헤테로원자를 함유하는 5원 헤테로사이클; (f) R4로부터 독립적으로 선택되는 1 내지 3개의 치환체에 의해 임의로 치환된, -O-, -NR2- 및 -S(O)n-으로 구성된 그룹에서 선택되는 두개 이하의 헤테로원자를 함유하는 6원 헤테로사이클; 또는 (g) 페닐 환에 융합된 5 또는 6원의 헤테로사이클릭 환으로 구성되고, 이때 상기 헤테로사이클릭 환은 R4로부터 독립적으로 선택되는 1 내지 3개의 치환체에 의해 임의로 치환된, -O-, -NR2- 및 -S(O)n-으로 구성된 그룹으로부터 선택되는 두개 이하의 헤테로원자를 함유하는 비사이클릭 환 시스템이고; Z1은 (a) -(CH2)pW(CH2)q-; (b) -O(CH2)pCR5R6-; (c) -O(CH2)pW(CH2)q-; (d) -OCHR2CHR3-; 또는 (e) -SCHR2CHR3-이고; G는 (a) -NR7R8; (b)상기 식에서 n은 0, 1 또는 2이고; m은 1, 2, 또는 3이고; Z2는 -NH-, -O-, -S-, 또는 -CH2-이고; 임의로 하나 또는 두개의 페닐 환과 인접한 탄소원자상에 융합되고, 임의로 1 내지 3개의 치환체에 의해 탄소상에서 독립적으로 치환되고, 임의로 R4로부터 선택된 화학적으로 적합한 치환체로 질소상에서 독립적으로 치환되거나; 또는 (c) 가교화되거나 융합되고 R4로부터 독립적으로 선택된 1 내지 3개의 치환체에 의해 치환된, 5 내지 12개의 탄소 원자를 함유하는 비사이클릭 아민이거나; 또는 Z1및 G는일 수 있고; W는 (a) -CH2-; (b) -CH=CH-; (c) -O-; (d) -NR2-; (e) -S(O)n-; (f);(g) -CR2(OH)-; (h) -CONR2-; (i) -NR2CO-; (j), 또는 (k) -C≡C-이고; R은 수소 또는 C1-C6알킬이고; R2및 R3은 독립적으로 (a) 수소; 또는 (b) C1-C4알킬이고; R4는 (a) 수소; (b) 할로겐; (c) C1-C6알킬; (d) C1-C4알콕시 (e) C1-C4아실록시; (f) C1-C4알킬티오; (g) C1-C4알킬설피닐; (h) C1-C4알킬설포닐; (i) 하이드록시(C1-C4)알킬; (j) 아릴(C1-C4)알킬; (k) -CO2H; (l) -CN; (m) -CONHOR; (n) -SO2NHR; (o) -NH2; (p) C1-C4알킬아미노; (q) C1-C4디알킬아미노; (r) -NHSO2R, (s) -NO2; (t) -아릴; 또는 (u) -OH이고; R5및 R6은 독립적으로 C1-C8알킬 또는 함께 C3-C10카보사이클릭 환을 형성하고; R7및 R8은 독립적으로 (a) 페닐; (b) 포화되거나 또는 불포화된 C3-C10카보사이클릭 환; (c) -O-, -N- 및 -S-로부터 선택된 두개까지의 헤테로원자를 함유하는 C3-C10헤테로사이클릭 환; (d) H; (e) C1-C6알킬; 또는 (f) R5또는 R6과 함께 3 내지 8원의 질소 함유 환을 형성하고; 선형 또는 환형의 R7및 R8은 C1-C6알킬, 할로겐, 알콕시, 하이드록시 및 카복시로부터 독립적으로 선택되는 3개 까지의 치환체에 의해 임의로 치환될 수 있고; R7및 R8에 의한 환은 임의로 페닐 환 융합될 수 있고; e는 0, 1 또는 2이고; m은 1, 2 또는 3이고; n은 0, 1 또는 2이고; p는 0, 1, 2 또는 3이고; q는 0, 1, 2 또는 3이다.
- 제1항에 있어서, 화학식 (1)의 화합물이 하기 일반식인 조성물 :여기서, G는이다.
- 제1항에 있어서, 화학식 (1)의 화합물이 시스-6-(4-플루오로-페닐)-5-[4-(2-피페리딘-1-일-에톡시)-페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올; (-)-시스-6-페닐-5-[4-(2-피롤리딘-1-일-에톡시)-페닐-5,6,7,8-테트라하이드로나프탈렌-2-올; 시스-6-페닐-5-[4-(2-피롤리딘-1-일-에톡시)-페닐-5,6,7,8-테트라하이드로나프탈렌-2-올; 시스-1[6'-피롤로디노에톡시-3'-피리딜]-2-페닐-6-하이드록시-1,2,3,4-테트라하이드로나프탈렌; 1-(4'-피롤리디노에톡시페닐)-2-(4-플루오로페닐)-6-하이드록시-1,2,3,4-테트라하이드로이소퀴놀린; 시스-6-(4-하이드록시페닐)-5-[4-(2-피페리딘-1-일-에톡시)-페닐]-5,6,7,8-테트라하이드로나프탈렌-2-올; 및 1-(4'-피롤리디놀에톡시페닐)-2-페닐-6-하이드록시-1,2,3,4-테트라하이드로이소퀴놀린으로 구성된 그룹에서 선택되는 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 알쯔하이머 질환인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 트롬보모듈린이 결핍인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 자궁 섬유증인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 과도한 미엘로퍼옥시다아제 활성인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 초과량의 트롬빈인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 자기면역 질환인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 허혈성 심근의 재관류 손상인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 테스토스테론 부전증인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 생리전 증후인 조성물.
- 제1항에 있어서, 상기 병리학적 증상이 폐경기전 증후인 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1321396P | 1996-02-28 | 1996-02-28 | |
| US60/013,213 | 1996-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970061256A true KR970061256A (ko) | 1997-09-12 |
Family
ID=21758835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970006291A KR970061256A (ko) | 1996-02-28 | 1997-02-27 | 에스트로겐 작용제에 의해 질환을 치료하기 위한 조성물 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5889042A (ko) |
| EP (1) | EP0792642B1 (ko) |
| JP (1) | JPH107564A (ko) |
| KR (1) | KR970061256A (ko) |
| CN (1) | CN1165655A (ko) |
| AT (1) | ATE204475T1 (ko) |
| AU (1) | AU703384B2 (ko) |
| CA (1) | CA2198562C (ko) |
| DE (1) | DE69706209T2 (ko) |
| DK (1) | DK0792642T3 (ko) |
| ES (1) | ES2159812T3 (ko) |
| GR (1) | GR3036874T3 (ko) |
| IL (1) | IL120267A (ko) |
| MX (1) | MX9701605A (ko) |
| MY (1) | MY118765A (ko) |
| PT (1) | PT792642E (ko) |
| TW (1) | TW442286B (ko) |
| ZA (1) | ZA971713B (ko) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| JP2004515446A (ja) | 1997-11-24 | 2004-05-27 | ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド | テストステロン阻害剤及びニューロンの保護のためのその用途 |
| EP1832598A3 (en) | 1999-09-30 | 2008-01-02 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| US6596261B1 (en) * | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| ATE333450T1 (de) | 2000-04-07 | 2006-08-15 | Pfizer Prod Inc | Metabolite von estrogen-agonisten/-antagonisten |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
| TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
| US7223552B2 (en) | 2001-01-02 | 2007-05-29 | The Cleveland Clinic Foundation | Myeloperoxidase, a risk indicator for cardiovascular disease |
| US7780950B2 (en) * | 2002-01-02 | 2010-08-24 | The Cleveland Clinic Foundation | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| DE60202678T2 (de) * | 2001-05-25 | 2006-04-06 | Gorm Danscher | Verfahren zur implantation von schwermetall, wie z.b. ein edelmetall, z.b. gold, und metall zur verwendung bei der implantation |
| WO2003055856A2 (en) * | 2001-10-17 | 2003-07-10 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
| US20040049134A1 (en) * | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
| PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| JP2006516276A (ja) * | 2003-01-22 | 2006-06-29 | ファイザー・プロダクツ・インク | エストロゲンアゴニスト／アンタゴニストを使用して、関節痛を治療または睡眠を改善する方法 |
| US7459286B1 (en) * | 2003-10-22 | 2008-12-02 | The Cleveland Clinic Foundation | Assessing the risk of a major adverse cardiac event in patients with chest pain |
| ATE546734T1 (de) | 2003-12-05 | 2012-03-15 | Cleveland Clinic Foundation | Risikomarker für eine herzkreislaufkrankheit |
| WO2006020498A2 (en) | 2004-08-11 | 2006-02-23 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
| EA026675B1 (ru) | 2010-06-16 | 2017-05-31 | Эндорешерш, Инк. | Способы лечения или предотвращения эстрогензависимых заболеваний |
| US10426754B2 (en) * | 2017-06-14 | 2019-10-01 | Anavex Life Sciences Corp. | Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
| SE452551B (sv) * | 1986-05-27 | 1987-12-07 | Camurus Ab | Artikel belagd med heparinbaserat material samt forfarande for dess framstellning |
| JPH04312526A (ja) * | 1991-04-09 | 1992-11-04 | Fujisawa Pharmaceut Co Ltd | 骨疾患治療剤 |
| US5364791A (en) * | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| DK0635264T3 (da) * | 1993-06-24 | 1997-10-20 | Lilly Co Eli | Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler |
| US5461065A (en) * | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
| US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
| US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
| US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
| US5418252A (en) * | 1993-10-15 | 1995-05-23 | Eli Lilly And Company | Method for inhibiting cartilage degradation |
| JPH07149638A (ja) * | 1993-10-15 | 1995-06-13 | Eli Lilly & Co | 耐性新生物の治療法 |
| US5672610A (en) * | 1993-12-21 | 1997-09-30 | Eli Lilly And Company | Methods of increasing macrophage function |
| US5521198A (en) * | 1993-12-21 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting autoimmune diseases |
| US5446053A (en) * | 1993-12-21 | 1995-08-29 | Eli Lilly And Company | Methods of inhibiting dysfunctional uterine bleeding |
| US5476862A (en) * | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
| US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| US5534526A (en) * | 1993-12-21 | 1996-07-09 | Eli Lilly And Company | Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome |
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| US5596004A (en) * | 1993-12-21 | 1997-01-21 | Eli Lilly And Company | Methods of inhibiting male infertility |
| CN1095663C (zh) * | 1993-12-21 | 2002-12-11 | 伊莱利利公司 | 抑制低密度脂蛋白氧化和动脉粥样硬化的方法 |
| US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
| US5461064A (en) * | 1993-12-21 | 1995-10-24 | Eli Lilly And Company | Methods of inhibiting atrophy of the skin and vagina |
| US5439923A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method of inhibiting seborrhea and acne |
| US5439931A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
| US5451589A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly And Company | Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism |
| US5451590A (en) * | 1993-12-21 | 1995-09-19 | Eli Lilly & Co. | Methods of inhibiting sexual precocity |
| US5708009A (en) * | 1993-12-21 | 1998-01-13 | Eli Lilly And Company | Methods of inhibiting myeloperoxidase activity |
| US5462950A (en) * | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of treating menstrual symptoms and compositions therefore |
| US5462949A (en) * | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of inhibiting fertility in women |
| US5441965A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
| US5441966A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
| US5389670A (en) * | 1993-12-21 | 1995-02-14 | Eli Lilly Company | Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder |
| US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
| AU8155694A (en) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Methods of inhibiting obsessive-compulsive and consumptive disorders |
| CZ321394A3 (en) * | 1993-12-21 | 1995-08-16 | Lilly Co Eli | Pharmaceutical preparation for inhibiting woman hirsutism and alopecia |
| US5384332A (en) * | 1994-05-11 | 1995-01-24 | Eli Lilly And Company | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
| US5455275A (en) * | 1994-05-11 | 1995-10-03 | Eli Lilly And Company | Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives |
| US5470883A (en) * | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
| US5441986A (en) * | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
| US5434166A (en) * | 1994-08-22 | 1995-07-18 | Eli Lilly And Company | Methods of inhibiting demyelinating and desmyelinating diseases |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
-
1997
- 1997-01-21 TW TW086100636A patent/TW442286B/zh not_active IP Right Cessation
- 1997-02-20 IL IL12026797A patent/IL120267A/en not_active IP Right Cessation
- 1997-02-21 EP EP97301150A patent/EP0792642B1/en not_active Expired - Lifetime
- 1997-02-21 ES ES97301150T patent/ES2159812T3/es not_active Expired - Lifetime
- 1997-02-21 DE DE69706209T patent/DE69706209T2/de not_active Expired - Fee Related
- 1997-02-21 AT AT97301150T patent/ATE204475T1/de not_active IP Right Cessation
- 1997-02-21 PT PT97301150T patent/PT792642E/pt unknown
- 1997-02-21 DK DK97301150T patent/DK0792642T3/da active
- 1997-02-21 US US08/803,706 patent/US5889042A/en not_active Expired - Fee Related
- 1997-02-26 CA CA002198562A patent/CA2198562C/en not_active Expired - Fee Related
- 1997-02-27 AU AU14980/97A patent/AU703384B2/en not_active Ceased
- 1997-02-27 MX MX9701605A patent/MX9701605A/es unknown
- 1997-02-27 KR KR1019970006291A patent/KR970061256A/ko not_active Application Discontinuation
- 1997-02-27 MY MYPI97000788A patent/MY118765A/en unknown
- 1997-02-27 ZA ZA971713A patent/ZA971713B/xx unknown
- 1997-02-28 CN CN97103415A patent/CN1165655A/zh active Pending
- 1997-02-28 JP JP9045905A patent/JPH107564A/ja active Pending
-
2001
- 2001-10-11 GR GR20010401737T patent/GR3036874T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0792642A1 (en) | 1997-09-03 |
| MX9701605A (es) | 1998-04-30 |
| DK0792642T3 (da) | 2001-10-08 |
| GR3036874T3 (en) | 2002-01-31 |
| DE69706209D1 (de) | 2001-09-27 |
| CN1165655A (zh) | 1997-11-26 |
| ATE204475T1 (de) | 2001-09-15 |
| AU703384B2 (en) | 1999-03-25 |
| IL120267A (en) | 2002-11-10 |
| IL120267A0 (en) | 1997-06-10 |
| AU1498097A (en) | 1997-09-04 |
| CA2198562A1 (en) | 1997-08-28 |
| MY118765A (en) | 2005-01-31 |
| ZA971713B (en) | 1998-08-27 |
| DE69706209T2 (de) | 2001-12-06 |
| TW442286B (en) | 2001-06-23 |
| JPH107564A (ja) | 1998-01-13 |
| US5889042A (en) | 1999-03-30 |
| PT792642E (pt) | 2001-12-28 |
| CA2198562C (en) | 2002-09-10 |
| ES2159812T3 (es) | 2001-10-16 |
| EP0792642B1 (en) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970061256A (ko) | 에스트로겐 작용제에 의해 질환을 치료하기 위한 조성물 | |
| KR970061254A (ko) | 에스트로겐 길항제 및 에스트로겐 작용제에 의해 병리학적 증상을 억제하기 위한 조성물 | |
| KR960029323A (ko) | 에스트로겐 작동제/길항제 | |
| KR100367793B1 (ko) | 아테롬성동맥경화증치료용제약조성물 | |
| LU91406I2 (fr) | Anidulafungine, optionnellement sous forme d'un sel pharmaceutiquement acceptable -ECALTA | |
| KR920006313A (ko) | 설폰아미드 피브리노겐 수용체 길항제 | |
| KR960701661A (ko) | AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS) | |
| RU96100074A (ru) | Агонисты/антагонисты эстрогена, фармацевтическая композиция, способ лечения заболеваний | |
| KR960704874A (ko) | 에스트로겐 작용물질로서의 벤조티오펜 및 관련 화합물 (benzothiophenes and related compounds as estrogen agonists) | |
| ATE423566T1 (de) | Augenbehandlung unter verwendung von cyclosporin a derivaten | |
| EP0354777A3 (en) | 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives | |
| AU531586B2 (en) | Morpholine derivatives | |
| US5086050A (en) | Method of treating inflammatory disorders and psoriasis with salts of azelastine | |
| KR850007799A (ko) | 퍼히드로티아제핀 유도체의 제조방법 | |
| KR880005093A (ko) | 5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물 | |
| KR970705559A (ko) | 신규한 벤즈이미다졸 유도체(novel benzimidazole derivatives having cgmp-phosphodisterase inhibiting activity) | |
| NZ332321A (en) | 3-Descladinose-2,3-anhydroerythromycin derivatives and medicaments | |
| KR970061255A (ko) | 폴리포스포네이트 또는 프로게스틴과 함께 에스트로겐 작용 물질을 사용하여 골다공증을 치료하기 위한 약학 조성물 | |
| ATE237614T1 (de) | Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren | |
| EP0889034A4 (en) | AMINOPYRIDINE DERIVATIVES | |
| AU583113B2 (en) | Carbapenem derivatives | |
| EP0521101A1 (en) | Topically active ocular benzothiazole sulfonamide carbonic anhydrase inhibitors | |
| JPS5398951A (en) | Azetidinone derivatives and process for their preparation | |
| ZA874938B (en) | Process for the preparation of pristinamycin 11b derivatives | |
| KR900701797A (ko) | α-아드레날린성 수용체 길항질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |